The NGS and molecular diagnostics for cancer treatment

4 September 2014

The sensitivity and the speed of the NGS would allow to identify all the coding sequences of genes linked to cancer. Thus NGS would be capable of identifying the substitution mutations and the insertions / deletions (indels), but could also define the transcribes of fusion as well as to copy the changes of number. It would then offer the possibility of using a unique platform to simultaneously analyze a multitude of genes. Its high sensitivity would also allow it to detect the presence of transformations that are quasi-undetectable with older analysis techniques.
This would then place the NGS as an almost ideal solution for molecular diagnostics in oncology. But at present, the only sequencer authorized in Europe and by the FDA, for applications of clinical diagnostics, is the MiSeqDx from Illumina.
Furthermore, the pharmaceutical industry and Illumina are still in the development phase for a universal system for oncology tests